Nimbus Therapeutics announces positive topline results for Ph2b clinical trial of allosteric TYK2 inhibitor

Clinical Impact

Nov 30

Written By Frances Benson

https://www.nimbustx.com/2022/11/30/nimbus-therapeutics-announces-positive-topline-results-for-phase-2b-clinical-trial-of-allosteric-tyk2-inhibitor-in-psoriasis/

2022

Frances Benson

HotSpot Therapeutics launches strategic collaboration with AbbVie to further expand immunology pipeline

Rezo Therapeutics, founded by renowned UCSF scientists, raises $78M in Series A